Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
There is an urgent need for the development of new therapeutic agents for the treatment of debilitating central nervous system (CNS) diseases, which affect millions of people worldwide. While the discovery and development of new therapeutic agents are challenging for all therapeutic areas, CNS drug discovery efforts have been especially challenging and have a very high attrition rate. The GPCRs have been among the most fruitful targets for developing drugs for the treatment of CNS disorders, as well as a range of other human disease states. Many current clinical therapeutic agents act by targeting this important receptor class and downstream signaling pathways.
For a long time, drug discovery programs for GPCR ligands have been dominated by efforts to develop agonists and antagonists which act at orthostatic sites for endogenous ligands. Nevertheless, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs which act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.
The study of GPCRs provides a promising new strategy with potential for developing novel treatments for many CNS disorders. As a global leader in drug discovery industry, Creative Biogene can offer a variety of GPCR related products including stable cell lines, viral particles and clones for your drug discovery projects in CNS disorders.
Copyright © Creative Biogene. All rights reserved.